MedTrace Logo

UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

NCT04658056 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2020-12-08

No results posted yet for this study

Summary

A post-market, non-interventional, two-arm, long-term follow-up study of patients previously enrolled in the WATER Study (NCT02505919) - which was a prospective multi-centre randomized blinded study comparing Aquablation of the prostate with the AQUABEAM Robotic System with standard transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS).

Conditions

  • Benign Prostatic Hyperplasia
  • Lower Urinary Tract Symptoms

Sponsors & Collaborators

  • PROCEPT BioRobotics

    lead INDUSTRY

Principal Investigators

  • Claus Roehrborn, MD · UT Southwestern Medical

  • Peter Gilling, MD · Tauranga Urology Research Limited

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-31
Primary Completion
2022-01-31
Completion
2022-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04658056 on ClinicalTrials.gov